Leonteq Securities’s Cullinan Therapeutics CGEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$230K Sell
15,000
-15,000
-50% -$287K 0.01% 476
2026
Q2
$546K Buy
30,000
+20,000
+200% +$297K 0.02% 389
2026
Q1
$142K Buy
+10,000
New +$129K 0.01% 666
2022
Q4
– Sell
-5,000
Closed -$64.1K – 1303
2022
Q3
$64.1K Hold
5,000
– – ﹤0.01% 747
2022
Q2
$64.1K Buy
5,000
+1,000
+25% +$11.3K ﹤0.01% 772
2022
Q1
$41.9K Buy
+4,000
New +$54K ﹤0.01% 894

Other funds holding CGEM

Leonteq Securities's CGEM Position: Q3 2026 in Review

Leonteq Securities reduced its Cullinan Therapeutics (CGEM) stake by 50% in Q3 2026, selling an estimated $287K and leaving 15,000 shares worth $230K. The position accounts for 0.01% of the portfolio, ranked #476.

Leonteq Securities first reported a position in CGEM in Q1 2022 and has held it in 6 quarters since. The position peaked at $546K in Q2 2026. 180 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.

  • Leonteq Securities held 15,000 shares of Cullinan Therapeutics worth $230K as of Q3 2026.
  • Leonteq Securities sold 15,000 Cullinan Therapeutics shares in Q3 2026, an estimated $287K.
  • Cullinan Therapeutics made up 0.01% of Leonteq Securities's portfolio in Q3 2026, its #476 holding.
  • Leonteq Securities first reported a position in Cullinan Therapeutics in Q1 2022 and has held it in 6 quarters since.
  • Leonteq Securities's Cullinan Therapeutics position peaked at $546K in Q2 2026.
  • 180 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.

Based on Leonteq Securities's 13F filing for Q3 2026, filed 29 Oct 2026.